| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 4 nov 2026Próximo | Q3 2026 | Antes de apertura | -1,22 | 894 M |
2 sept 2026
In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...
1 sept 2026
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.
The company progresses its mRNA-based candidate just under a month after Moderna won FDA approval for the first seasonal flu mRNA vaccine.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Moderna stock led the index after melanoma vaccine data, while a hedge fund's forced unwind turbocharged a rebound in enterprise software
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: * Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a. ET * Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.
